elotuzumab   Click here for help

GtoPdb Ligand ID: 8361

Synonyms: BMS-901608 | Empliciti® | HuLuc63
Approved drug Immunopharmacology Ligand
elotuzumab is an approved drug (FDA (2015), EMA (2016))
Compound class: Antibody
Comment: Elotuzumab is a humanized IgG1 antibody targeting CS1 (SLAMF7) [1-2].
Peptide sequences for elotuzumab are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al.. (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin Cancer Res, 14 (9): 2775-84. [PMID:18451245]
2. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al.. (2008)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood, 112 (4): 1329-37. [PMID:17906076]
3. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R et al.. (2009)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol Cancer Ther, 8 (9): 2616-24. [PMID:19723891]
4. Veillette A, Guo H. (2013)
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Crit Rev Oncol Hematol, 88 (1): 168-77. [PMID:23731618]
5. Williams M, Tso JY, Landolfi NF, Powers DB, Liu G. (2010)
Therapeutic use of anti-CS1 antibodies.
Patent number: US7709610. Assignee: Facet Biotech Corporation. Priority date: 28/05/2003. Publication date: 04/05/2010.